Lupin Q2FY19 Result Expectation

Lupin is expected to report continued weakness in its US business due to higher competition in its large generic products. We expect 5% yoy growth in revenue while EBITDA and PAT are expected to decline 29% and 37% yoy, respectively.

To Get Free Trial 
Missed call @ 9582541010 
Call Us @ 8822117117 
Mail Us = starindiamarket@gmail.com 
Visit = http://www.starindiaresearch.com/freetrail.php